Director B Lynne Parshall filed a Form 144 notice with the SEC on November 9, 2026, disclosing a proposed sale of 5,000 shares of Cytokinetics, Incorporated common stock on NASDAQ.

Key Highlights

  • Proposed sale: 5,000 shares of Cytokinetics common stock with an aggregate market value of $268,450.00.
  • Seller: B Lynne Parshall, identified in the filing as a Director of Cytokinetics, Incorporated.
  • Source of shares: The 5,000 shares were acquired on May 14, 2026, from the issuer through Restricted Stock Units.
  • Shares outstanding: The filing reports 139,303,351 shares outstanding as of the notice date.
  • Prior 3-month sales: The filing discloses a prior sale of 5,000 shares on September 1, 2026, with gross proceeds of $357,404.00, also under a 10b5-1 plan.
  • 10b5-1 plan: The notice references a Rule 10b5-1 plan adopted on August 10, 2026, as the basis for the proposed sale.
  • Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Parshall's Proposed Stock Sale Under 10b5-1 Plan at Cytokinetics

According to the Form 144 notice filed on November 9, 2026, B Lynne Parshall, a Director at Cytokinetics, Incorporated (NASDAQ:CYTK), intends to sell 5,000 shares of the company's common stock. The filing lists an approximate sale date of November 9, 2026, with an aggregate market value of $268,450.00. The shares are to be sold on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services.

The filing discloses that the 5,000 shares proposed for sale were acquired on May 14, 2026, from the issuer through Restricted Stock Units, with payment listed as "N/A." The notice also indicates that Parshall adopted a Rule 10b5-1 written trading plan on August 10, 2026, and that the proposed sale is being conducted in reliance on that plan. By signing the form and indicating the plan adoption date, the filer made the representation that she did not know any material adverse information regarding the issuer's current and prospective operations that had not been publicly disclosed, as stated in the filing's attestation language, as of the plan adoption date.

The filing further reports that within the prior three months, Parshall sold 5,000 shares of Cytokinetics common stock on September 1, 2026, generating gross proceeds of $357,404.00, also identified as a 10b5-1 sale. As of the filing date, the company's total shares outstanding are reported as 139,303,351.

What Was Disclosed

Cytokinetics Director B Lynne Parshall filed a Form 144 on November 9, 2026, notifying the SEC of a proposed sale of 5,000 common shares with an aggregate market value of $268,450.00, to be executed under a 10b5-1 plan adopted August 10, 2026.